FDA Final Approval Announced November 14 for Generic Binimetinib 15 mg and 45 mg Tablets: the 45 mg Strength Is New, and Both Strengths Carry 180 Days of Generic Exclusivity

Alembic Pharmaceuticals announced on November 14 that the U.S. Food and Drug Administration (FDA) has granted final approval to its abbreviated new drug application (ANDA) for binimetinib tablets in 15 mg and 45 mg strengths. The generic is therapeutically equivalent to the reference listed drug Mektovi, held by Array BioPharma, a subsidiary of Pfizer. Binimetinib is a kinase inhibitor that inhibits MEK and is used in combination with the BRAF inhibitor encorafenib for patients with BRAF-mutant melanoma and non-small cell lung cancer.
The reference product is supplied in the United States only as 15 mg tablets, so the 45 mg tablet is a new strength for U.S. patients and clinicians. Alembic was one of the first applicants to file a substantially complete ANDA with a Paragraph IV certification for the 15 mg strength and the sole first applicant for the 45 mg strength, making it eligible for 180 days of generic drug exclusivity for both strengths. The company had previously received tentative approval for the 15 mg strength and, in June 2026, for the 45 mg strength.
With this approval, Alembic's cumulative FDA ANDA approvals reach 248, comprising 230 final approvals and 18 tentative approvals.
The announcement did not state when the generic will launch in the United States and did not include pricing information. It records the approval and the exclusivity eligibility only; this report presents the approval facts and the company's announcement, offers no advice on individual treatment, and notes that therapy decisions rest with treating clinicians and the approved labeling.
Published by GSM · USA (original Chinese edition)
Photo: Wikimedia Commons, File:Superficial spreading melanoma in situ on dermoscopy, reflectance confocal microscopy and histopathology 1.jpg — Authors: Juliana Casagrande Tavoloni Braga, Mariana Petaccia Macedo, Clovis Pinto, João Duprat, Maria Dirlei Begnami, Giovanni Pellacani, Gisele Gargantini Rezze (PLOS ONE, 2013). Licensing: CC BY 4.0.
STEP Young Phase 3 Trial in The New England Journal of Medicine, Announced November 16: BMI Fell 17.4% at Week 68 in 167 Children Aged 6 to Under 12, Versus a 2.2% Rise on Placebo2026-11-16
FDA Approves MYQORZO Label Update on November 16: Phase 3 MAPLE-HCM Data Added, With the Week 24 Peak Oxygen Uptake Endpoint Met and Five of Six Secondary Endpoints Significantly Improved2026-11-16